Please assess the completion status of the following clinical trial:

Trial Title: Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent must be obtained before any assessment is performed.~2. Male or female participants ≥ 18 years of age at screening~3. Participants should meet fasting serum LDL-C ≥ 100 mg/dL (≥ 2.6 mmol/L) at screening~4. Participants should meet fasting triglyceride \< 400 mg/dL (\< 4.52 mmol/L) at screening~5. Participants should be receiving a maximally tolerated dose of statin#.~6. For all participants, all the lipid-lowering therapy/ies (such as but not limited to statins and/or ezetimibe) should have remained stable (stable dose and no medication change) for ≥ 30 days before screening with no planned medication or dose change during study participation. #Maximum tolerated dose was defined as the maximum dose of statin that could be taken on a regular basis without intolerable AEs.~7. Participants not receiving statin must have a documented evidence of intolerance to all doses of at least 2 different statins (or the corresponding local definition of complete intolerance to statins)~Exclusion Criteria:~1. Participants diagnosed with any of following: homozygous familial hypercholesterolemia, New York Heart Association class III \& IV heart failure, Type 2 diabetes, severe hypertension, active liver disease, HIV infection or any uncontrolled or serious disease;~2. History of drug abuse or unhealthy alcohol use, malignancy of any organ system, or or allergy to the investigational compound/compound class;~3. Major adverse cardiovascular event within 3 months prior to randomization;~4. Calculated glomerular filtration rate ≤30 mL/min by estimated glomerular filtration rate (eGFR) using standardized clinical methodology;~5. Use of other investigational drugs or planned use of other investigational products or devices;~6. Women of child-bearing potential unless they are using basic methods of contraception during dosing of investigational drug (total abstinence, sterilization, barrier methods, hormonal contraception, intrauterine device);~7. Treatment with monoclonal antibodies inhibiting PCSK9 within 90 days prior to screening.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 300 mg inclisiran sodium (equivalent to 284 mg inclisiran) (Type: EXPERIMENTAL): 300 mg inclisiran sodium (equivalent to 284 mg inclisiran) x 1 dose (n=15) at Day 1
- 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) (Type: EXPERIMENTAL): 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) x 1 dose (n=15) at Day 1
- Placebo (Type: PLACEBO_COMPARATOR): Placebo x 1 dose (n=10) at Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete